REGN846
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pruritus
Conditions
Pruritus, Atopic Dermatitis
Trial Timeline
Jun 1, 2012 → Apr 1, 2013
NCT ID
NCT01605708About REGN846
REGN846 is a phase 1/2 stage product being developed by Regeneron Pharmaceuticals for Pruritus. The current trial status is terminated. This product is registered under clinical trial identifier NCT01605708. Target conditions include Pruritus, Atopic Dermatitis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01605708 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Pruritus